With the rise in cancer, especially among younger populations, Johnson & Johnson appears set on profiting from this market.
The pharmaceutical giant paid $2 billion in cash to acquire Ambrx Biopharma, a company specializing in cancer treatment.
— Jake P. Noch (@Jake_P_Noch) January 11, 2024
“Johnson & Johnson announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired,” the company announced.
From Johnson & Johnson:
Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple cancer indications, including ARX517, its proprietary ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, its proprietary ADC targeting human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305, its proprietary ADC targeting CD-70 for renal cell carcinoma.
“Ambrx’s ADC technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads, which results in engineered ADCs that effectively kill cancer cells and limit toxicities,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. “The results seen to date with ARX517 in mCRPC are promising and represent a potential first- and best-in-class targeted therapy for the treatment of this aggressive disease. In addition, Ambrx’s pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics as we look to transform the treatment of cancer and improve patients’ lives.”
The planned acquisition presents a distinct opportunity for Johnson & Johnson to design, develop and commercialize targeted oncology therapeutics. Ambrx’s proprietary ADC technology incorporates the advantages of highly specific targeting monoclonal antibodies securely linked to a potent chemotherapeutic payload to achieve targeted and efficient elimination of cancer cells without the prevalent side-effects typically associated with chemotherapy. Building on a legacy of innovation in oncology and in prostate cancer, J&J scientists intend to work with Ambrx researchers, accelerating the Phase 1/2 APEX-01 study (NCT04662580) of ARX517 in advanced prostate cancer, while progressing a pipeline of novel ADC product candidates.
“We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs,” said Daniel J. O’Connor, Chief Executive Officer of Ambrx.
“With our deep and unique knowledge of precision engineering of protein therapeutics enabled by our proprietary technology incorporating synthetic amino acids in living cells, Ambrx has developed next generation novel drug candidates such as site-specifically conjugated highly stable antibody drug conjugates. Through this transaction, we will continue to advance our leading prostate cancer candidate and Ambrx’s promising pipeline, while delivering significant and certain cash value to our shareholders. This announcement is the culmination of two decades of scientific work, combined with the Ambrx team’s talent, hard work and innovation. I look forward to what Ambrx will achieve as part of Johnson & Johnson,” he added.
Ambrx is aiming to target multiple cancers with drugs called antibody-drug conjugates, or ADCs, which are described by researchers as “guided missiles” to directly target and kill cancer cells and minimize damage to healthy tissue.
The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs following similar moves by other large rivals – including Pfizer, AbbVie and Merck – over the last year.
The acquisition also comes as J&J scrambles to fill a revenue hole that’s approaching in 2025, when its top-selling drug Stelara, which is used to treat a long-lasting autoimmune disease called psoriasis, is expected to face generic competition.
“Johnson & Johnson to acquire $2 billion drug developer ‘Ambrx Biopharma’ to treat Turbo Cancers with same tech as Pfizer’s $43 billion Seagen acquisition. Both set their sights on 2025 Cancer TSUNAMI,” Dr. William Makis writes.
“Pfizer & Moderna COVID-19 mRNA Vaccines cause Turbo Cancers, this is now well acknowledged by respected physicians around the world. Last month, Pfizer closed a $43 billion acquisition of Seagen, to boost its ability to treat 7 of the top 10 Turbo Cancers caused by its COVID-19 mRNA Vaccine,” he added.
NEW ARTICLE: Johnson & Johnson to acquire $2 billion drug developer "Ambrx Biopharma" to treat Turbo Cancers with same tech as Pfizer's $43 billion Seagen acquisition. Both set their sights on 2025 Cancer TSUNAMI
Pfizer & Moderna COVID-19 mRNA Vaccines cause Turbo Cancers, this… pic.twitter.com/Ehl9UvXl8s
— William Makis MD (@MakisMD) January 17, 2024
Top 5 Turbo Cancers: lymphoma, glioblastoma, breast, colon, lungAdvertisement
Top 10 Turbo Cancers: leukemia, melanoma, sarcomas, testicular/ovarian, kidney
Pfizer expects a “Cancer Tsunami” to hit in 2025
Moderna is rushing its melanoma mRNA Cancer vaccine to have expedited approval by 2025.
Johnson & Johnson is the latest to want a piece of the Turbo Cancer treatment pie before 2025.
This $2 billion acquisition of Ambrx Biopharma gives them the same cancer treatment tech as Pfizer – ADCs.
ADC: “a class of therapeutics that combines the specificity of monoclonal antibodies with the potency of cytotoxic drugs, aiming to target and destroy cancer cells more effectively”
Johnson & Johnson, for $2 billion, adds new ability to treat Breast Turbo Cancer, Prostate Turbo Cancer and Kidney Turbo Cancer with this acquisition.
They also overpaid by more than 100% of the current Ambrx Biopharma stock price. Acquisition expected to close in mid 2024.
Many pharmaceutical companies are rushing to position themselves to profit from treating a tsunami of cancers that they are all expecting to hit starting in 2025.
Dec.14, 2023 – Pfizer closed a $43 billion acquisition to treat several turbo cancers and expects to “fill a gap” for the period 2025-2030.
Dec.14, 2023 – Moderna targets new mRNA Cancer vaccine to treat melanoma to be available by 2025
Jan.8, 2024 – Johnson & Johnson to acquire $2 billion cancer drug company that uses same tech as Pfizer, to “fill a revenue gap starting in 2025”
Jan.10, 2024 – BioNTech expects to return to revenue growth in 2025, when its COVID vaccine business would bottom out, and it would invest to “scale up its oncology business thereafter”
Many companies that have new blood tests or light tests to quickly detect cancer are all targeting 2025 for their launch. I provide examples.
Dozens of giant Cancer Centers are going up all across the US, Canada, Australia and UK – all of them are opening in 2025.
They’re ready for the 2025 Cancer TSUNAMI.
Read more about ‘Turbo Cancer‘: